Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
AstraZeneca Finland, Medaffcon and clinical experts have investigated what is the rarer endotype of severe asthma using biomarker data obtained from the data lake of Turku University Hospital (TYKS), Auria.
Samuli Tuominen, senior data scientist at Medaffcon, has co-authored a study that utilised propensity-score matching to compare the performance of two immunosuppressive drugs in patients with primary sclerosing cholangitis after liver transplantation. Medaffcon has helped to validate the superiority of tacrolimus over cyclosporine as a post-liver transplantation immunosuppressive regimen for patients with primary sclerosing cholangitis, a rare immune-mediated cholestatic liver disease.
Dr. Essi Havula has done an impressive international career as a researcher and top scientist. She joins Medaffcon team to strengthen the scientific possibilities of utilizing real-world-data and evidence.
Medaffcon in September added two new members to its team of data scientists, preparing itself for an era where pharmaceutical development and innovation are driven increasingly by real-world data. “Real-world evidence is getting bigger and bigger and we’re getting more and more research assignments, so we need smart minds and quick fingers to do all the data science,” sums up Iiro Toppila, data analysis lead at Medaffcon.
Experts at Medaffcon have perused volumes of real-world data on patients with atopic dermatitis to provide new insights into co-morbidities and treatment patterns associated with the chronic skin condition.
Experts from Medaffcon, Takeda and the Hospital District of Helsinki and Uusimaa (HUS) have concluded an extensive study into paediatric short-bowel syndrome based on information from patient records.
Sweden’s abundance of high-quality digital healthcare data has enabled what is surely one of the most exhaustive study of mortality associated with Clostridioides difficile infections (CDI) in the world.
Studies mapping short-term absences provide new information on the burden caused by diseases for healthcare services and the society.
Research based on Finnish and Swedish real-world health data can be generalised also to other settings and populations, says Dr. Johanna Simin, real-world epidemiologist at Medaffcon.
Joining Medaffcon enables Dr. Johanna Simin to leverage her expertise to advance real-world data use and evidence-driven health. Medaffcon, in turn, can augment its in-house capabilities with the high-quality digital healthcare data found in Sweden.
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
Register study undisputedly confirms that a smoker’s risk for any postoperative complications is significantly higher than non-smokers’.
Finnish hospitals’ data lakes offer an opportunity to access tremendously rich real-world data on treatments and outcomes that enable research on topics ranging from medical questions to health economics.
The result of a recent original study surprised the researchers: the costs of treating heart failure tenfold in exacerbation. The results were published in Duodecim on 23 March 2023.
How to review and analyse a million sentences? Text mining decreased the work of clinical experts and accelerated the research process.
Finland has unique data for pharmaceutical purposes and unstructured healthcare data can also be already effectively utilised.
Medaffconin Tanja Nieminen ja Heini Honkanen osallistuivat terveystaloustieteen tutkimukseen ja terveydenhuollon menetelmien arviointiin keskittyvään ISPOR-kongressiin marraskuussa.
Single-arm research designs are challenging for a pharmaceutical reimbursement and marketing authorisation process.
Finnish Social and Health Data Permit Authority Findata has significantly reformed and accelerated the processing...
It would be useful to have RWE support the decision-making related to managed introduction and...
In health economic studies, real world evidence (RWE) can produce additional knowledge, especially on the...
The basic reimbursement granted for medicinal substance teduglutide was a significant step forward for children...
We already have clinical medicine trials. Why on earth do we also need real world...
Utilisation of real-world evidence (RWE) progresses at speed and development steps are fast. Utilising real-world...
Studies relying on real-world evidence help clinicians to create a better overall picture of the...
The results of studies based on real-world data (RWD) have convinced also people that were...
RWE or real-world evidence provides authorities assessing pharmacotherapies with data on the prevalence of a...
Medaffcon expands its network of companies to Omicron ApS and Value Coaching Oy to extend...
OSLO, Norway/ ESPOO, Finland May 24, 2021 LINK Medical, the Northern European clinical research organization...
DLIMI and Medaffcon join forces to provide research-based pharmaceutical companies with Nordic Real World Evidence...
Interested in RWE research? Health from data is the first real-world evidence themed blog written...
Real World Evidence (RWE) ecosystem in Finland Real world data (RWD) is defined by FDA...
The real world data (RWD) landscape in Finland offers globally unique data and possibilities to...
Medaffcon pioneering biobank and real-world evidence research efforts in Finland The newest Biobanking in Finland...
BC Platforms AG, a world leader in genomic data management and analytics, today announces that...
Recently established Finnish hospital biobanks have launched new research activity in Finland. Through the Finnish biobank...
Medaffcon has in collaboration with the University of Eastern Finland assessed the operational status of...
Demonstrating that a health technology, e.g. a product, procedure or any intervention, is worth its...
In the Medaffcon customer evening organised in April 2017, we went through data sources related...